Patents by Inventor Heinrich Rüeger

Heinrich Rüeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazine derivatives and their use in the treatment of disease
    Patent number: 9163011
    Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: October 20, 2015
    Assignee: NOVARTIS AG
    Inventors: Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Siem Jacob Veenstra
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20150203481
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: September 10, 2014
    Publication date: July 23, 2015
    Applicant: NOVARTIS AG
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Konstanze HURTH, Sebastien JACQUIER, Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20150150877
    Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: February 5, 2015
    Publication date: June 4, 2015
    Applicant: NOVARTIS AG
    Inventors: Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Siem Jacob VEENSTRA
  • Pyrazolopyrrolidine derivatives and their use in the treatment of disease
    Patent number: 8975417
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Vincent Bordas, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
    Publication number: 20140378450
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Robin Alec FAIRHURST, Pascal FURET, Clive MCCARTHY, Heinrich RUEEGER, Frank Hans SEILER, Frédéric STAUFFER
  • Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease
    Publication number: 20140349990
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 8865712
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 21, 2014
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Oxazolidin-2-one compounds and uses thereof
    Patent number: 8865894
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: October 21, 2014
    Assignee: Novartis AG
    Inventors: Giorgio Caravatti, Robin Alec Fairhurst, Pascal Furet, Frédéric Stauffer, Frank Hans Seiler, Clive McCarthy, Heinrich Rueeger
  • Novel Oxazine Derivatives and their use in the Treatment of Disease
    Publication number: 20140256715
    Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Applicant: NOVARTIS AG
    Inventors: Konstanze Hurth, Sebastien Jacquier, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Oxazolidin-2-one-Pyrimidine Derivatives
    Publication number: 20140135330
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 15, 2014
    Applicant: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephan Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20140107118
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicant: NOVARTIS AG
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Konstanze HURTH, Sebastien JACQUIER, Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 8637508
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sébastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
    Publication number: 20130281449
    Abstract: The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: January 11, 2012
    Publication date: October 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Konstanze Hurth, Rainer Martin Lueoend, Rainer Machauer, Ulf Neumann, Heinrich Rueeger, Michael Schaefer, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20130172331
    Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: August 23, 2012
    Publication date: July 4, 2013
    Inventors: Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Siem Jacob VEENSTRA
  • Oxazine derivatives and their use in the treatment of neurological disorders
    Patent number: 8338413
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: December 25, 2012
    Assignee: Novartis AG
    Inventor: Heinrich Rueeger
  • OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20120302558
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: July 13, 2011
    Publication date: November 29, 2012
    Inventors: Sangamesh Badiger, Murali Chebrolu, Mathias Frederiksen, Philipp Holzer, Konstanze Hurth, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Ulf Neumann, Rita Ramos, Heinrich Rueeger, Michael Schaefer, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle, Lei Li, Hui Liu, Xin Xiong
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20120184539
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 19, 2012
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Konstanze HURTH, Sébastien JACQUIER, Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
    Publication number: 20120172359
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 5, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Mathias FREDERIKSEN, Philipp HOLZER, Konstanze HURTH, Rainer Martin LUEOEND, Lei LI, Hui LIU, Rainer MACHAUER, Henrik MOEBITZ, Ulf NEUMANN, Rita RAMOS, Heinrich RUEEGER, Michael SCHAEFER, Siem Jacob VEENSTRA, Marina TINTELNOT-BLOMLEY, Markus VOEGTLE, Xin XIONG
  • Alternative synthesis of renin inhibitors and intermediates thereof
    Patent number: 8143416
    Abstract: The present invention relates to synthetic routes to prepare a compound of the formula wherein R1 is halogen, C1-6halogenalkyl, C1-6alkoxy-C1-6alkyloxy or C1-6alkoxy-C1-6alkyl; R2 is halogen, C1-4alkyl or C1-4alkoxy; R3 and R4 are independently branched C3-6alkyl; and R5 is cycloalkyl, C1-6alkyl, C1-6hydroxyalkyl, C1-6alkoxy-C1-6alkyl, C1-6alkanoyloxy-C1-6alkyl, C1-6aminoalkyl, C1-6alkylamino-C1-6alkyl, C1-6dialkylamino-C1-6alkyl, C1-6alkanoylamino-C1-6alkyl, HO(O)C—C1-6alkyl, C1-6alkyl-O—(O)C—C1-6alkyl, H2N—C(O)—C1-6alkyl, C1-6alkyl-HN—C(O)—C1-6alkyl or (C1-6alkyl)2N—C(O)—C1-6alkyl; or a pharmaceutically acceptable salt thereof as well as key intermediates obtained when following these routes as well as their preparation.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: March 27, 2012
    Assignee: Novartis AG
    Inventors: Gottfried Sedelmeier, Stuart John Mickel, Heinrich Rueeger
  • Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors
    Patent number: 8093406
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: January 10, 2012
    Assignee: Novartis AG
    Inventors: Emmanuelle Briard, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Olivier Rogel, Jean-Michel Rondeau, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra